SG11201500309VA - Baclofen and acamprosate based therapy of macular degeneration disorders - Google Patents

Baclofen and acamprosate based therapy of macular degeneration disorders

Info

Publication number
SG11201500309VA
SG11201500309VA SG11201500309VA SG11201500309VA SG11201500309VA SG 11201500309V A SG11201500309V A SG 11201500309VA SG 11201500309V A SG11201500309V A SG 11201500309VA SG 11201500309V A SG11201500309V A SG 11201500309VA SG 11201500309V A SG11201500309V A SG 11201500309VA
Authority
SG
Singapore
Prior art keywords
baclofen
macular degeneration
based therapy
degeneration disorders
acamprosate
Prior art date
Application number
SG11201500309VA
Other languages
English (en)
Inventor
Daniel Cohen
Ilya Chumakov
Serguei Nabirochkin
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Publication of SG11201500309VA publication Critical patent/SG11201500309VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SG11201500309VA 2012-07-18 2013-07-18 Baclofen and acamprosate based therapy of macular degeneration disorders SG11201500309VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261672893P 2012-07-18 2012-07-18
PCT/EP2013/065209 WO2014013025A1 (en) 2012-07-18 2013-07-18 Baclofen and acamprosate based therapy of macular degeneration disorders

Publications (1)

Publication Number Publication Date
SG11201500309VA true SG11201500309VA (en) 2015-02-27

Family

ID=48794112

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201500309VA SG11201500309VA (en) 2012-07-18 2013-07-18 Baclofen and acamprosate based therapy of macular degeneration disorders

Country Status (17)

Country Link
US (1) US9545389B2 (enrdf_load_stackoverflow)
EP (1) EP2874617B1 (enrdf_load_stackoverflow)
JP (1) JP6271539B2 (enrdf_load_stackoverflow)
KR (1) KR20150058159A (enrdf_load_stackoverflow)
CN (1) CN104780917B (enrdf_load_stackoverflow)
AU (1) AU2013291970B2 (enrdf_load_stackoverflow)
BR (1) BR112015001090A2 (enrdf_load_stackoverflow)
CA (1) CA2879114A1 (enrdf_load_stackoverflow)
EA (1) EA029157B1 (enrdf_load_stackoverflow)
ES (1) ES2729208T3 (enrdf_load_stackoverflow)
IL (1) IL236737B (enrdf_load_stackoverflow)
IN (1) IN2015DN00820A (enrdf_load_stackoverflow)
MX (1) MX364232B (enrdf_load_stackoverflow)
NZ (1) NZ704280A (enrdf_load_stackoverflow)
SG (1) SG11201500309VA (enrdf_load_stackoverflow)
WO (1) WO2014013025A1 (enrdf_load_stackoverflow)
ZA (1) ZA201500663B (enrdf_load_stackoverflow)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2727587A1 (en) 2012-10-30 2014-05-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
EP3062782A1 (en) 2013-10-30 2016-09-07 Pharnext Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
EP3104850A1 (en) 2014-02-11 2016-12-21 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1485082A4 (en) 2002-02-19 2009-12-30 Xenoport Inc PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS
AU2004267100B2 (en) 2003-08-20 2010-10-07 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
WO2005027950A1 (en) * 2003-09-12 2005-03-31 Ray And Terry's Health Products, Inc. Eye nutritional supplement
DK1716115T3 (da) 2003-12-30 2013-05-27 Xenoport Inc Syntese af acyloxyalkylcarbamat-prodrug og mellemprodukter deraf
ES2365574T3 (es) 2007-01-11 2011-10-07 Xenoport, Inc. Formas de dosificación oral para liberación continua de un profármaco de r-baclofeno y procedimientos de tratamiento.
JP2010532331A (ja) * 2007-07-05 2010-10-07 アンセルム(アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル) 抗痙攣医薬組成物
US20090082464A1 (en) 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
EP2217564A1 (en) 2007-09-07 2010-08-18 XenoPort, Inc. Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090099253A1 (en) 2007-10-15 2009-04-16 Xenoport, Inc. Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use
US20090118365A1 (en) 2007-11-06 2009-05-07 Xenoport, Inc Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
WO2009096985A1 (en) 2008-02-01 2009-08-06 Xenoport, Inc. Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment
US20100137442A2 (en) 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
WO2010089355A1 (en) * 2009-02-04 2010-08-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
AU2010221270B2 (en) * 2009-03-03 2014-02-27 Xenoport, Inc. Sustained release oral dosage forms of an R-baclofen prodrug
JP2012524065A (ja) 2009-04-17 2012-10-11 ゼノポート,インコーポレーテッド GABAB受容体リガンドとしてのγ−アミノ酪酸誘導体
EP2680835B1 (en) * 2011-03-01 2018-02-07 Pharnext Treatment of cerebral ischemia

Also Published As

Publication number Publication date
CN104780917B (zh) 2017-09-08
WO2014013025A1 (en) 2014-01-23
MX364232B (es) 2019-04-16
IL236737B (en) 2018-12-31
IL236737A0 (en) 2015-02-26
CA2879114A1 (en) 2014-01-23
NZ704280A (en) 2017-06-30
JP2015522601A (ja) 2015-08-06
EP2874617A1 (en) 2015-05-27
ES2729208T3 (es) 2019-10-30
US9545389B2 (en) 2017-01-17
US20150238452A1 (en) 2015-08-27
IN2015DN00820A (enrdf_load_stackoverflow) 2015-06-12
AU2013291970A1 (en) 2015-02-19
CN104780917A (zh) 2015-07-15
EA029157B1 (ru) 2018-02-28
HK1209335A1 (en) 2016-04-01
AU2013291970B2 (en) 2017-09-28
MX2015000777A (es) 2015-10-14
BR112015001090A2 (pt) 2017-06-27
ZA201500663B (en) 2016-10-26
EP2874617B1 (en) 2019-02-27
KR20150058159A (ko) 2015-05-28
JP6271539B2 (ja) 2018-01-31
EA201500143A1 (ru) 2015-05-29

Similar Documents

Publication Publication Date Title
ZA201306039B (en) Baclofen and acamprosate based therapy of neurogical disorders
IL269852B (en) Combined treatments and uses for the treatment of demyelination disorders
IL266582A (en) Preparations and methods for the treatment of hemoglobin diseases
ZA201500561B (en) Compositions and treatment for eye diseases and disorders
SG2014008080A (en) Methods of treatment of retinal degeneration diseases
EP2925775A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLISM DISEASES AND DRESSINGS
HUE041553T2 (hu) Lizoszomális tárolási betegségek (LSD) kezelése és génterápia
IL239368A0 (en) Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system
IL233639A0 (en) Preparations and methods for the treatment of diseases and liver disorders
IL237772A0 (en) Methods and preparations for the treatment of retinal degeneration
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
ZA201500663B (en) Baclofen and acamprosate based therapy of macular degeneration disorders
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
HRP20181945T1 (hr) Liječenje neuroloških poremećaja na bazi baklofena i akamprozata
HK40043513B (en) Interval therapy for the treatment of eye diseases
HK1196022A (zh) 视网膜变性疾病的治疗方法